Akèy › Leksemi mieloïd egi › New York › Rochester
Etid klinik pou Leksemi mieloïd egi nan Rochester, NY
16 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Rochester General Hospital, Rochester
- University of Rochester, Rochester
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Rochester, Rochester
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- University of Rochester Medical Center, Rochester
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Rochester, Rochester
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Rochester, Rochester
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- University of Rochester, Rochester
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- University of Rochester, Rochester
A Telehealth Advance Care Planning Intervention
Ap rekrite
- University of Rochester, Rochester
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Wilmot Cancer Institute, University of Rochester, Rochester
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Ap rekriteFaz 3
- University of Rochester Medical Center (URMC), Rochester
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Strong Memorial Hospital/University of Rochester, Rochester
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Ap rekrite
- University of Rochester Medical Center, Rochester
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Ap rekriteFaz 1 bonè
- Wilmot Cancer Institute, University of Rochester, Rochester
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Ap rekriteFaz 1/2
- The University of Rochester, Rochester
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
Ap rekriteEtid obsèvasyon
- University of Rochester Medical Center, Rochester
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Ap rekriteVolontè an sante akeyi
- University of Rochester, Rochester
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Rochester
- Kansè poumon15 etid
- Kansè nan tete15 etid
- Kansè (tout kalite)14 etid
- Obèsite14 etid
- Sipwa13 etid
- Kansè Poumon ki pa ti selil13 etid
- Kansè pwostat10 etid
- Kansè Metastatik8 etid
- Myelom Miltip8 etid
- Kansè vejik7 etid
- Distrofi myotonik7 etid
- Kansè pankreyas7 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.